Clinuvel Pharmaceuticals Limited (CUV.AX)
ASX - ASX Delayed price. Currency in AUD
Add to watchlist
At close: 04:10PM AEST
| Previous close | 14.89 |
| Open | 15.01 |
| Bid | 14.90 x 84100 |
| Ask | 15.03 x 12400 |
| Day's range | 14.95 - 15.40 |
| 52-week range | 12.96 - 21.53 |
| Volume | |
| Avg. volume | 141,144 |
| Market cap | 751.408M |
| Beta (5Y monthly) | 0.74 |
| PE ratio (TTM) | 26.30 |
| EPS (TTM) | 0.57 |
| Earnings date | 22 Feb 2024 |
| Forward dividend & yield | 0.05 (0.33%) |
| Ex-dividend date | 05 Sept 2023 |
| 1y target est | 26.41 |
Simply Wall St.Is Clinuvel Pharmaceuticals Limited's (ASX:CUV) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?
Clinuvel Pharmaceuticals' (ASX:CUV) stock is up by a considerable 8.7% over the past month. Since the market usually...
GlobeNewswirePhotomedicine Pioneer CLINUVEL Unveils Clinical, Cosmetic Ambitions to German Investors
DÜSSELDORF, Germany, March 28, 2024 (GLOBE NEWSWIRE) -- Pioneering biopharmaceutical company CLINUVEL yesterday hosted a wide-ranging market briefing discussing its novel drug SCENESSE® (afamelanotide) and the future of photomedicine. Over 70 guests discussed the Company’s unique history and future growth potential at an invitation-only event in Düsseldorf. Managing Director and CEO, Dr Philippe Wolgen shared the Company’s success in establishing profitability over the past seven financial years
- Simply Wall St.
Clinuvel Pharmaceuticals (ASX:CUV) shareholders have endured a 50% loss from investing in the stock three years ago
Investing in stocks inevitably means buying into some companies that perform poorly. Long term Clinuvel Pharmaceuticals...
© 2024 Yahoo. All rights reserved.